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The differential expression of the ACE2 receptor across
ages and gender explains the differential lethality of
SARS-Cov-2 and SARS and suggests possible therapy.
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Abstract
The fatality rate of SARS-Cov-2 escalates with age and is larger in men than
women. I show that these variations are strongly correlated with the levels of the
ACE2 protein in the lungs but surprisingly, despite ACE2 is the viral receptor,
higher levels lead to lower fatality. This behaviour is consistent with a previous
mathematical model that predicts that the speed of viral progression in the organ-
ism has a maximum and then declines with the receptor level. SARS-Cov-2 degrades
ACE2 and thus worsens lung injury, causes vasoconstriction, thrombotic problems,
and exacerbated inflammatory response. I developed a mathematical model based
on the influence of ACE2 on viral propagation and on the negative effects of its
degradation. The model fits SARS-CoV-2 fatality rate across age and gender with
high accuracy (r2 ≈ 0.9). Rescaling the model parameters with the binding rates
of the spike proteins of SARS-CoV and SARS-CoV-2 allows predicting the fatal-
ity rate of SARS-CoV across age and gender, in particular its higher severity for
young patients, thus linking the molecular and epidemiological levels. These results
support the suggestion that drugs that enhance the expression of ACE2, such as
ACE inhibitors and angiotensin receptor blockers, constitute a promising therapy
against the most adverse effects of CoViD-19. Furthermore, ACE2 is a candidate
prognostic factor for detecting population that needs stronger protection.
The Covid-19 pandemics [1] is causing thousands of fatalities worldwide [2], creating a
tremendous threat to global health. This disease presents a striking gradient of fatalities
across age and a marked gender bias that determines much higher severity for males than
for females. The first observation was generally attributed to the insurgence of comor-
bidities and the weakening of the immune system with age. The second observation was
initially attributed to the fact that men tend to smoke more than women [3]. This gender
difference is very marked in China where Covid-19 emerged but it is not so strong in other
countries where it spread later, raising doubts on this explanation. Indeed many experts
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wondered whether the gender difference should be attributed to some more fundamental
biological difference yet to be discovered [4].
To make this issue more puzzling, the infection fatality rate (IFR) of the covid-19
disease was estimated to be around 1% [5, 6]. This implies that, except in countries
that applied extremely intensive tests, at least 80-90% of the infections have not been
detected [6, 7], presumably because the symptoms were mild enough to be confused with
common cold. So, how does Covid-19 escalate from extremely weak symptoms in the
youngest age cohorts, where the fatality rate almost vanishes and hospitalization is not
needed, to 41% fatalities in male patients over 90 that had to be hospitalized, as reported
in Italy [8]? And, more important, is it possible to treat the disease so that the severity
of the most affected classes approaches that of the most protected ones?
Here I show that the variation of the case fatality rate (CFR), a commonly used
proxy of the IFR, across age and gender is very strongly correlated with the level of the
Angiotensin converting enzyme 2 (ACE2), the cellular receptor both of SARS and SARS-
CoV-2 virus [1, 11], in the lungs [12]. Although these data are obtained in rats, they are
qualitatively similar to ACE2 mRNA expression in human tissues [13]. This correlation
rationalizes the strong observed comorbidity between covid-19 and hypertension [3], since
hypertension is negatively related with ACE2 levels, which favour vasodilation.
Surprisingly, the correlation between ACE2 and lethality is strongly negative: higher
levels of the receptor decrease the lethality exponentially. The paradox is only apparent
if we adopt a previously developed mathematical model of virus dynamics [14]. Stated
in terms of receptor level, this model predicts that the speed of viral propagation is a
non-monotonic function of the receptor that reaches a maximum and then decreases at
high level. Here I extend this mathematical model for predicting the lethality of the
SARS-CoV-2 infection based on the assumption that patients die if the virus degrades
ACE2 in the lungs below a critical threshold before the immune system can control the
infection.
ACE2 [15–17] is a key component of the Renin Angiotensin System (RAS) that regu-
lates blood pressure and electrolyte homeostasis in blood [18] together with the homolo-
gous enzyme ACE, whose action it counteracts. While ACE cleaves angiotensin I (AngI)
to produce angiotensin II (AngII), a peptide that binds to the AT1R receptor producing
vasoconstriction and increasing blood pressure, ACE2 cleaves angiotensin II to angiotensin
1-7, a peptide with vasodilator effect, thereby reducing blood pressure. ACE2 protects the
lungs from severe injury induced by acid aspiration or sepsis [19, 20], and it counteracts
the pro-inflammatory effect of AngII [26,27]. Upon viral entry the spike proteins of both
SARS-CoV and SARS-CoV-2 cause the internalization and degradation of ACE2 that
critically contributes to lung damage [20, 21]. Decrease of ACE2 activity through SARS
infection [22] or aging [23] exacerbate the severity of lung injuries and inflammatory lung
diseases [21]. Dis-balance of ACE2 with respect to ACE, and the resulting high blood
pressure are known to enhance the prothrombotic state [24, 25] and the inflammatory
state [26, 27], producing symptoms frequently observed in severe SARS-CoV-2 patients.
The mathematical model that considers the influence of ACE2 on viral progression
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and the negative effects of its degradation predicts the CFR of SARS-CoV-2 across six
classes of age and gender in Italy, Spain and Germany, which span 3 orders of magnitude,
with goodness-of-fit r2 ≈ 0.90. Importantly, the model fitted to SARS-CoV-2 and rescaled
with the ratio between the binding rates of the spike proteins of SARS-CoV and SARS-
CoV-2 allows predicting the SARS-CoV CFR with very good agreement. In particular,
it predicts that SARS-CoV is relatively more severe for younger ages than SARS-CoV-
2, as observed, suggesting that simple mathematical models can successfully bridge the
molecular and the epidemiological level.
Results
Age- and gender-specific lethality is negatively correlated with
ACE2 level
Due to its relevance as the SARS receptor, the levels of the ACE2 protein in rat lungs were
quantified by Xie et al. across three age classes of the two genders [12]. These authors
found that the level of the ACE2 protein in the lungs strongly decays with age and it is
generally larger for female than for male rats, with largest differences in the oldest cohort
where the expression is almost double for female than for male rats.
Strikingly, the expression profile of ACE2 is very strongly anti-correlated with the
lethality profile of SARS-CoV-2, as shown in Fig.1. This figure represents the level of
the ACE2 protein in lung rats measured by Xie et al. (horizontal axis, data from Fig.2
of [12]) versus the case fatality ratio (CFR) of CoVid-19 registered in Italy [8], Spain [9]
and Germany [10] in three uniform age classes (young, 0-29, middle-age 30-59 and old
> 60; vertical axis) of the two genders. The data strongly support the exponential decrease
of mortality with ACE2 concentration. The exponential fit is excellent, with r2 = 0.91,
0.97 and 0.89, respectively, indicating that variations of ACE2 describe the largest part
of the variation of the CFR.
As for other two-parameter fits tested in this work, the fitted exponent for Italy and
Germany coincide within the error and the CFR differ only for a multiplicative factor,
supporting the robustness of the data. Compared with these countries, data from Spain
present higher mortality in the young ages. This can be attributed to the fact that
the undetected cases are more frequent in classes where the disease is less severe but,
puzzlingly, the estimated fraction of undetected cases is similar in Spain and Italy [6].
Although the ACE2 protein levels were obtained in rats, a recent preprint that anal-
ysed the GTEx database found the same qualitative trends in human mRNA expression
across several tissues: ACE2 expression tends to be higher in women than in men and
tends to decrease with age [13]. Protein levels are more relevant for COVID-19 infection,
but the trends are the same. Additional arguments that support the validity of rat data
also for humans will be discussed later.
The GTEx database also shows that, despite lungs are the organ that is more severely
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Figure 1: Expression of the ACE2 protein in lung rats (horizontal axis), normalized so
that the highest expression is one, versus case fatality rate (vertical axis) of SARS-CoV-2
(Circles: Italy; triangles: Spain; diamonds: Germany) and SARS 2003 (open squares) in
three age classes (young 0-29, middle-age 30-59 and old > 59) and two genders (male and
female). The solid lines represent fits to the mathematical model (see text), the dashed
lines represent predictions that rescale the models fitted to SARS-CoV-2 with the ratio
between the binding rate constants of SARS and SARS-CoV-2 (see text).
damaged by COVID-19, they are not the tissue with the highest expression of ACE2
mRNA [30]. ACE2 expression is higher in tissues from reproductive organs, intestine,
adipose tissue, kidney, hearth, thyroid, esophagus, breast, salivary glands and pancreas,
among others. Some of these organs my be infected but they experience less damage,
consistent with the negative correlation between ACE2 levels in lungs and lethality.
Mathematical model of covid-19 lethality
To rationalize the negative correlation between receptor expression and lethality I devel-
oped a mathematical model that assumes that Covid-19 deaths arise if the virus propa-
gates through the upper respiratory tract (URT) reaching the lungs and it degrades the
ACE2 receptor below a critical level before the immune system takes control.
The dynamics is crucial in this formulation. Since ACE2 is the viral receptor, we may
expect that raising the ACE2 level enhance the rate at which SARS-CoV2 propagates
in the organism and make the outcome of the infection worse. This reasoning lead to
propose that drugs that stimulate the expression of ACE2, such as ACE inhibitors (ACE-
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i) and angiotensin receptor blockers (ARB) that treat high blood pressure, may increase
the risk of severe COVID-19 [28,29]. However, a mathematical model of viral progression
shows that other outcomes are possible. Mathematical models of viral growth consider
three processes: virus adsorption into susceptible cells, production of virus by infected cells
after a delay time, and viral clearance by the immune system [31]. I shall translate here all
the mathematical results in terms of receptor density, exploiting that the adsorption rate
is proportional to the receptor level A expressed in susceptible cells times the association
rate between the virus and the receptor, kA ≡ kA. In the simple mean-field version in
which space is not considered, the model predicts that there is a minimal receptor density
below which the virus does not grow and above that the initial growth rate of the virus
is proportional to the adsorption rate kA, implying that higher receptor levels accelerate
the viral progression.
Nevertheless, virus propagate with finite velocity, and considering spatial diffusion
modifies important predictions and parameters of the mathematical model. Luckily, the
analytical solution of a mathematical model of viral infection in space is available [32].
This model was tested with experiments on the spread of bacteriophages in lysis plaques,
but its mathematical formulation is conceptually equivalent to the above and can be
directly applied to the present setting. As a function of the receptor level A (adsorption
rate in the original paper), the authors describe two regimes: (1) when A is small the
viral velocity v increases less than linearly with A. (2) For intermediate kA, large with
respect to the delay time τ but small with respect to the rate at which viral particles are
produced, the viral velocity depends on the effective diffusion constant and it is almost
independent of A [32], so that the viral progression is not enhanced by the expression of
the receptor.
Importantly, the formulas presented in Ref. [32] are also valid in the third regime of
very high receptor density, when kA is larger than the rate at which viral particles are
produced, although this regime is not explicitly discussed. Counter-intuitively, in this
regime the viral progression slows down with receptor density as v ∝ 1/
√
kA. This result
is surprising: how can the virus progression be slowed down by increasing the receptor
level? Since this is a mathematical model, the answer is readily found: in the model,
viral particles are consumed when they enter a cell but the viral yield per infected cell
does not increase when a cell is infected multiple times. Indeed, it was even proposed
that multiple viral entries in the same cell interfere with viral replication. In fact, several
viruses such as HIV [33,34], measles [35], influenza [36] and hepatitis B [37] downregulate
their own receptor to prevent multiple viral entries. These observations support the idea
that, after the infection is established, very fast adsorption is not advantageous for the
virus, which also agrees with a recent study that demonstrated the protective effect of
high adsorption rate through analytic computation, simulation and experiment [38]. All
together, the mathematical model predicts the existence of a receptor level for which the
viral progression is fastest.
Adopting these formulas it is possible to compute the time td after which the virus
enters the lungs and degrades ACE2 below a critical level, causing the death of the patient,
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as a function of the initial level of ACE2, A (see Methods).
Next, I compute the lethality in each class as the probability that td is smaller than
the time ti needed by the immune system for neutralizing the virus. I model ti as a
random variable, and consider two simple distributions: (1) The exponential distribution,
which is the distribution with maximum entropy for given average value.(2) The Gaussian
distribution, which is justified by the fact that the limit of the sum of independent random
variables is a Gaussian variable and ti is the sum of intermediate steps in the maturation
of the immune response. I neglect differences in immune system parameters from one age
and gender class to the other in order to test if variations of the receptor level alone can
explain the lethality data only through. This assumption is discussed later.
For the two tested distributions, it is easy to compute the lethality as a function
of A in the three possible dynamical regimes in which the viral velocity increases, is
constant, and decreases with the receptor level A (see Methods). In the increasing regime
lethality is an increasing function of A. This behaviour contradicts the data and I shall
not consider it further. If the velocity is constant the death probability is a decreasing
function of A because, at larger initial values, it takes more time to degrade the receptor
below the critical level. I call this situation Model 1. If the velocity decreases the death
probability is a decreasing function of A even without considering this critical level (Model
2). Finally, Model 3 considers both the decrease of the velocity with A and the effect
of the critical level of ACE2. The three models, combined with the exponential and the
Gaussian distribution, predict different functional forms of the CFR versus A and they can
be tested by fitting their predictions to the data (see Methods). Under both distributions,
and for the CFR of all the tested countries, model 1 has the worst fit and model 3 the
best. In particular, under the exponential distribution the relative quadratic error of the
logarithm for models 1, 2 and 3 is 0.37, 0.19, 0.07, respectively, for Spain, 0.41, 0.30, 0.21
for Italy and 0.48, 0.23, 0.17 for Germany. Adopting the Gaussian distribution there is one
additional parameter, with high risk of overfitting, but the ranking remains clear: 0.04,
0.01 and 0.01 for Spain, 0.10, 0.04 and 0.04 for Italy and 0.14, 0.06, 0.06 for Germany,
so that model 1 performs the worst and it is not possible to discriminate models 2 and
3. See Methods and Supplementary Table 1) for further details. In all cases the fits are
regularized through rescaled ridge regression [67] to reduce over-fitting. In summary, the
hypothesis that the viral velocity decreases with the receptor density fits the data fairly
well and it is preferable to the hypothesis of constant velocity, while present data do not
allow assessing the effect of the critical level of ACE2.
The solid lines plotted in Fig.1 represent approximate fits of model 2 under the Gaus-
sian distribution: − log(CFR) = aA− b
√
A + c. They yield r2 > 0.92 with only two free
parameters, since the parameter c was not fitted to reduce the error but it is necessary for
obtaining the correct sign of the parameter b (see Methods). The differences of parameters
a and b between countries only slightly exceed the statistical errors. They may reflect
the different incidence of undetected cases that affect different age classes differently (see
Methods).
An important prediction of the model is that the fit parameters depend on the ad-
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sorption constant per unit receptor, k, as a ∝ k and b ∝
√
k. Crucially, this prediction
can be tested on the CFR of the 2003 SARS coronavirus [39], which also uses ACE2 as
its cellular receptor. I hypothesize that the rate-limiting step in adsorption is the binding
of the spike protein and the receptor, if their affinity is large enough to allow membrane
fusion, a hypothesis supported by infection assays. Thus, I assume that k is proportional
to the binding rate constant between the spike and ACE2 that has been characterized
with biochemical experiments. Equipped with these data, we rescale the fit parameters a
and b obtained for SARS-CoV-2 to predict the corresponding parameters for SARS (see
Methods) and multiply the predicted CFR times a global factor that accounts for the
different fraction of undetected cases, which is the only free parameter. The prediction
is very good, yielding relative quadratic error equal to 0.13, 0.08 and 0.010 using the fit
parameters from Italy, Spain and Germany, respectively, see Fig.1, table 1 and Discussion.
It is natural to extend this analysis to the other coronavirus that uses ACE2 as recep-
tor, NL63 [40] that causes common cold and is not generally associated with pneumonia.
Its spike protein contains a very stable receptor binding domain of 120 residues (482-602)
that was crystallized and showed high binding affinity for ACE2 [41]. However, the com-
plete S1 domain of the spike (717 residues) is much less stable and its affinity for ACE2
is much smaller than for SARS-CoV [40, 42, 43]. Its affinity is so small that it was not
possible to measure it with binding assays and it was conjectured that it is 10-100-fold
smaller than that of SARS-CoV [42]. Since the CFR of SARS peaks for old females, whose
normalized ACE2 is equal to 22% of the maximum value, and stays constant for old males
with lower ACE2, the model predicts that this is the level at which SARS-CoV propagates
fastest. If the binding affinity of the NL63 spike is at least ten times smaller, the ACE2
level at which NL63 propagates fastest is more than double the highest ACE2 level in
the lungs, predicting that NL63 is in the regime in which ACE2 expression enhances its
propagation. Consistently, NL63 infection is usually acquired during childhood [40], when
the levels of ACE2 are higher. This analysis agrees with the apparently surprising data
reported in Fig.3A of Ref. [40], which shows that ACE2 overexpression in 293T cells en-
hances NL63 infection three times more than SARS-CoV infection, indicating that higher
receptor levels accelerate more the propagation of NL63 than that of SARS-CoV-2 despite
the latter has higher binding affinity.
Discussion
This work suggests that variations of the level of the protein ACE2 in the lungs largely
explain the variation of the lethality of the CoVid-19 disease across six age and gender
classes whose CFR span 3 decades. ACE2 is used by the SARS-Cov-2 virus and the related
SARS-Cov and NL63 virus as entry point in the cells, so that it has been proposed that
its high concentration has an adverse effect and that drugs that stimulate ACE2 should
be avoided in the context of the Covid-19 pandemics [28,29]. Quite oppositely, we found
that an increasing concentration of ACE2 decreases exponentially the lethality.
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This result can be rationalized by a previous mathematical model that analytically
predicts that the speed of viral progression in an infected organ reaches a maximum as
a function of the receptor level and then decreases at higher values [32]. This happens
because viral particles that enter cells that are already infected are consumed without
increasing the viral yield. Furthermore, it has been proposed that multiple viral entries in
the same cell hinder the maturation of viral particles. This effect is thought to underlay
the evolution of mechanisms that limit the co-infection of the same cell by multiple viral
particles by downregulating their own receptor after successful cell entry [33–37]. This
tendency of some virus to downregulate their receptor was noted by Gurwitz for arguing
against the idea that ACE2 expression favours SARS-CoV-2 infection [44].
Consistent with these results, the lungs are the organ where SARS-CoV-2 produces
the largest damage but they rank only 19 among 54 human tissues for the expression level
of ACE2, according to the GTEx database [30].
I developed a set of six mathematical models that predict the lethality of each age-
gender class as a function of its ACE2 level in the lungs based on three elements. (1)
The analytical prediction of how the receptor level influences viral propagation. (2) The
hypothesis that the degradation of ACE2 is the main causative factor of the patients
death, which occurs if the ACE2 level decays below a critical threshold before the immune
system is able to control the infection. (3) The time necessary for the immune system
to control the virus, which is modelled either as an exponential or as a Gaussian random
variable. I neglected the dependence of these distributions on age and gender for two
reasons. First, there are not reliable data on age- and gender-specific immune system
parameters. Second and most important, I want to test the hypothesis that the levels
of ACE2 alone are sufficient to determine the lethality profile without considering that
the immune response weakens with age. This does not mean that the immune senescence
is not important, but data can be explained even without considering it. The immune
systems of male and female persons of middle age do not exhibit large differences, but
their average ACE2 level and the SARS-CoV-2 lethality are different.
The resulting mathematical models provide excellent fits to the observed age and
gender specific mortality rates, and the best model is the one that assumes that the
propagation of the virus is slowed down by the receptor level, which fits data from the
three countries with high accuracy (r2 > 0.92). Six data points is a small number, but
the variation that they span is large and the agreement between data and model is very
strong.
Strikingly, the fitted models also allow predicting the lethality profile across age and
gender of the 2003 SARS-CoV outbreak from the measured ratio between the binding rate
constants of the spike proteins of SARS and SARS-CoV-2, without free parameters except
a global scale factor. The relative mean square error is 0.13, 0.08 and 0.010 using the fit
parameters from Italy, Spain or Germany, respectively. Beside this surprising quantitative
agreement, the most important aspect is the qualitative prediction that SARS has a higher
relative incidence of mortality in young age with respect to old age compared with SARS-
CoV-2 (the ratio is 22% compared with 1.3%). This is one of the most striking differences
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between the two diseases, and we can qualitatively predict it from the fact that the SARS
spike protein has smaller binding rate constant than SARS-CoV-2, bridging the molecular
and the epidemiological level through a mathematical model of virus progression.
This prediction appears anti-intuitive: SARS is less efficient at binding its receptor,
and nevertheless it is more lethal for younger ages. This comparison brings the worrying
prediction that a mutation that decreases the binding affinity of the spike protein may
generate a strain that is more lethal at younger ages.
Finally, the mathematical model predicts that the NL63 coronavirus, whose spike pro-
tein has much smaller binding affinity, is in a regime in which the receptor level enhances
the viral progression. This is consistent with the fact that it is widespread among chil-
dren that have the highest levels of the receptor, and with some apparently odd results
reported in Ref. [40].
One limitation of the present work is that I used data of ACE2 protein expression
obtained in rat lungs [12]. Nevertheless, a recent preprint that analysed the GTEx
database [30] found the same qualitative trends of ACE2 mRNA expression in several
human organs: ACE2 is more expressed in female than in male subjects, and its ex-
pression decays with age [13]. Furthermore, several arguments support the portability of
expression data from rats to humans. First, there is an almost exact factor two between
ACE2 expression in old female and male rats, as expected from the fact that the ACE2
gene is contained in the X chromosome both in rats and in humans, and females have two
copies of it while males have only one. ACE2 is regulated by sex hormones [45], and the
gender difference in level is very small for young rats, which suggests that young males
compensate the disadvantage of having a single copy of the ACE2 gene overexpressing it.
This may be a protective mechanism against cardio-vascular diseases (CVD), since some
of the sex differences in CVD have been attributed to ACE2 [46]. Expression data show
that this overexpression fades with age until the factor two gender-difference in ACE2
expression is reached at old age. These features (X chromosome location, compensatory
overexpression in males that decays with age) are common between rats and humans. In
contrast, a recent clinical study could not find significant differences in ACE2 expression
between patients with acute respiratory distress syndrome (ARDS) of different age [47].
However, it is likely that the response to ARDS involves a complex dynamics of the RAS
system to which ACE2 belongs. The clinical study measured the activity of RAS en-
zymes at only one time point for each patient, so that the dynamics may have obscured
the individual differences.
Short after the discovery of ACE2, it was shown that this enzyme protects against
lung damage in a mouse model of diffuse alveolar damage [19]. SARS and SARS-CoV-2
infections lead to degradation of ACE2, with detrimental effects on the lungs [20–22,55].
Low levels of ACE2 increase the levels of AngII, which exacerbates the inflammatory
response [26, 27], as it is observed in the most severe CoViD-19 cases, and they can also
lead to the prothrombotic state that causes coagulation problems [24,25], another frequent
complication of CoViD-19 patients. Similar arguments were presented in two very recent
papers that also propose that downregulation of ACE2 is the main responsible of the
9
complications arising in severe CoViD-19 cases [61, 62].
Recent clinical studies in China and Italy support the beneficial role of ACE2 in
protecting the lungs and mitigating the severity of COVID-19 [49, 50, 52, 54]. Already
at the time of SARS, a retrospective meta-analysis found that the use of ACE-I provide
a consistent reduction in risk of pneumonia compared with controls, in particular in
patients with stroke and heart failure [56]. However, this protective role of ACE2 and of
ACE-I and ARB that enhance its expression has been out-weighted by its role as entry
point of SARS-Cov and SARS-Cov-2 in the cells, and it was speculated that ARB and
ACE-I may favour the viral progression and should be avoided [28, 29]. Several medical
societies expressed firm statements opposing this suggestion, arguing that it lacks sufficient
evidence [58–60]. The current consensus is that data in humans are too limited to support
either hypothesis that ACE-I and ARB may be detrimental or beneficial in COVID19
infections, but withdrawal of anti-hypertensive drugs in patients that need them may be
harmful [53].
The strong negative correlation between ACE2 levels and lethality of SARS-Cov-2
found in this work, and the mathematical prediction that the receptor level does not
enhance but it may even slow down the viral progression, support the clinical evidence
that the effect of ACE2 on survival is positive and suggests two complementary protective
roles of high ACE2 levels. On one hand, they are predicted to slow down the propaga-
tion of the virus, an effect conceptually similar to the one observed in recent experiments
with soluble human ACE2 [57]. On the other hand, they alleviate the most severe com-
plications of CoViD-19 and increase the time after which ACE2 is degraded below the
critical level, giving more time to the immune system to fight against the virus. This
work thus supports the idea that the drugs that upregulate ACE2 level, such as ACE
inhibitors (ACE-I) and angiotensin receptor blockers (ARB) used to treat high blood
pressure [15, 48], may reduce the lethality of old age classes towards the one of younger
individuals and provide a promising treatment against the most adverse manifestations of
CoViD-19. The same proposal has been recently advocated by Gurwitz and by Verdecchia
et al. among others [44, 61], and critical trials sponsored by the University of Minnesota
(NCT04312009,NCT04311177) started in April 2020. It would be desirable that other
clinical trials join the effort to assess this rather promising treatment.
Finally, the results presented here suggest a prognostic role for the measurements of
ACE2 levels, which may predict the severity of the disease already at an early stage and
may allow detecting risk groups besides the elder. Indeed, hypertension is an important
comorbidity of COVID-19 [3] that can be explained by the fact that both diseases are
made more severe by lower levels of ACE2, supporting the hypothesis that individuals
with low levels of ACE2 have to be protected more by the consequences of SARS-CoV-2
infection.
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Materials and Methods
Case-fatality-rates and expression data
Case fatality rates (CFR) were taken from Ref. [8–10] for CoViD-19 in Italy, Spain and
Germany, respectively, and from Ref. [39] for the 2003 SARS outbreak in Hong-Kong.
At the beginning of an outbreak, CFR underestimate the true fatality rate because their
calculation assumes that all people currently infected will recover, which unfortunately
is not true. This effect may not be uniform across age-gender classes if patients of some
classes tend to die more rapidly, as assumed by the model. However, at a late epidemic
stage this effect is expected to be small. On the other hand, CFR overestimate the true
fatality rate because of undetected cases that tend to lower the denominator. Since age-
gender classes with higher lethality also tend to have more severe cases and less undetected
cases, the overestimation is larger for classes with smaller lethality, with the consequence
of reducing the differences among classes for larger fraction of undetected cases. The
data currently available do not allow correcting for this bias, which may account for some
of the differences in the fit parameters. The current data suggest that the fraction of
undetected cases was roughly similar between Spain and Italy and it was much smaller
for Germany [6].
Expression data presented in Ref. [12] were grouped in three age classes of 3 (young),
12 (middle) and 24 months (old). CFR were presented in bins of 10 years, and I grouped
them in three equally spaced groups 0-29 (young), 30-59 (middle) and ≥ 60 years (old).
Grouping the 20-29 years class with the middle age gave similar results with approximately
exponential decrease of lethality with ACE2 expression.
For SARS CFR [39], ages were grouped differently: 0-44 (young), 45-74 (middle) and
≥ 75 (old). To compare these groups with those of SARS-CoV-2, I interpolated expression
data of ACE2 A for these groups as A(0 − 44) = 0.667A(0 − 29) + 0.333A(30 − 59),
A(45 − 74) = 0.5A(30− 59) + 0.5A(≥ 60) and A(≥ 75) = 0.667A(≥ 60). Other schemes
gave qualitatively similar results: The CFR decreases approximately exponentially with
A and the exponent is smaller than for SARS-CoV-2, which are the two important points
made in the paper.
Mathematical model of viral propagation
The simplest mathematical model of viral propagation considers three populations: un-
infected cells U(t), free virus V (t) that enter the cells with rate kAU(t)V (t) (adsorption)
and are cleared with rate c, and infected cells I(t) that produce new virus at rate kV Y I(t)
(Y stands for yield) after a delay τ called eclipse time, until they ultimately die [31]. Here
I express the adsorption rate as a function of the receptor density A, kA = kA. The viral
population cannot grow below the minimum receptor density given by Amin = c/(kU0Y )
(U0 is the initial concentration of susceptible cells). A spatially explicit version of this
model in which virus diffuse through susceptible cells [14] was found amenable to ana-
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lytical solution that explicitly gives the viral velocity v as a function of the model pa-
rameters [32]. Here I describe this solution in terms of the receptor density. The authors
describe two regimes: (1) For small A (A < 1/(kU0τY ), A < 1/(kU0kV )), the viral ve-
locity increases with A, but less then linearly, as v = 2
√
D kAU0Y
1+kAU0Y
. (2) For intermediate
receptor density 1/(kU0τY ) < A < 1/(kU0kV ) the viral velocity is given by v =
√
2D/τ ,
where D is the effective diffusion constant that depends on cell shape and density, and
it is almost independent of A [32] so that the viral progression is not enhanced by the
expression of the receptor. (3) The formulas presented in the paper are also valid in the
third regime of very high receptor density, when kA is larger than the rate at which viral
particles are produced: A > 1/(kU0τY ), A > 1/(kU0kV )), although this regime was not
explicitly discussed. Counter-intuitively, in this regime the viral progression slows down
with receptor density as v =
√
kV /kAU0.
The time that it takes for the virus to propagate through the upper respiratory tract
(URT) can be estimated as tU = lU/v. When the virus reaches the lungs, the number of
infected cells grows with time as I(t) ∝ (vt)dF , where dF ≈ 2.35 is the fractal dimension
of the lungs [63], which are one of the classical examples of a fractal organ. As cells get
infected, the receptor density in the lungs decreases as A(t) = A(0)
(
1− I(t)/ldFL
)
and it
reaches the critical level Ac after the time tL = (lL/v)(1−Ac/A0)1/dF ≈= lLv
(
1− Ac
dF
1
A(0)
)
.
I used the approximation Ac ≪ A(0), and A(0) is the receptor density at the beginning of
the infection, which in the main text is simply denoted as A. Summing these two times,
I estimate the time at which death occurs as td ≈ (1/v)
[
lU + lL
(
1− Ac
dF
1
A
)]
.
I consider three situations: (1) v is independent of A; (2) v decreases as 1/
√
kA and
almost all the cells in the lungs must be infected to produce the death, i.e. Ac = 0; (3)
v decreases with A and Ac > 0. In each situation, the death time td depends on A as
td ∝ 1− AcdF
1
A
(Model 1), td ∝
√
k
√
A (Model 2), td ∝
√
k
(√
A− Ac
dF
1√
A
)
(Model 3).
In the model, death occurs if td is smaller than the time ti needed by the immune
system to control the virus, which is modelled either as an exponential (E) or a Gaussian
(G) random variable. In the first case, the probability that ti is larger than td can be
computed as Pd = exp(−td/T ), where T is the average value of ti. In the Gaussian case,
the probability is well approximated as Pd = C exp (−(td − µ)2/(2σ2)). Combining these
expressions with the three models of td versus A and grouping together terms with the
same power of A, we obtain six mathematical models of the lethality Pd as a function of
the initial level of ACE2 A:
− ln(Pd) ≈


− a
A
+ b (1E) a
A2
− b
A
+ c (1G)
a
√
A+ b (2E) aA− b
√
A+ c (2G)
a
√
A− b√
A
(3E) aA− b
√
A+ c√
A
(3G)
a, b and c are positive fitting parameters. In Eq.(3G), there are five terms proportional
to A,
√
A, 1/
√
A, 1/A and constant, corresponding to five fitting parameters. In order to
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fit only three parameters, the same number as for the other Gaussian fits, I neglected the
terms proportional to 1/A and constant, obtaining Eq.(3G), while neglecting the terms
proportional to 1/A and 1/
√
A yields Eq.(2G).
Fits of the model
I determine the fitting parameters a, b, c through regularized fits performed with rescaled
ridge regression [67], which minimizes the quadratic error plus the term Λ(a2 + b2 + c2)
that penalizes large values of the parameters. The regularization is necessary to avoid
amplifying the noise due to covariant explanatory variables, as in the present case, and
it allows more robust parameter estimation, often avoiding that they acquire unphysical
values with incorrect sign, at the price of some bias. Rescaled ridge regression yields
non vanishing parameters even in the limit of very large Λ, overcoming a drawback of
other regularization schemes, and it fixes the parameter Λ based on an analogy with
statistical mechanics at the transition between the phase dominated by the noise and the
one dominated by the bias. For ridge regression there is no analytic formula to determine
the statistical error of the fitting parameters, therefore I applied a bootstrap approach,
repeating the fit while eliminating each of the data points and computing the standard
deviation of the fitting parameters numerically.
Despite these cautions, three-parameter fits of only six points are prone to overfitting,
but when the Gaussian distribution was considered the two parameters fits yielded some
parameters with incorrect sign. In these cases, I scanned different values of the constant
c, I fitted − ln(Pd) − c = aA − b
√
A with only two free parameters and determined the
parameter c not by minimizing the error of the fit but by choosing a given value of the
relative error on the parameters (50%).
Prediction for SARS
The models fitted to SARS-CoV-2 were rescaled in order to apply them to SARS-CoV,
adopting the ratio between the binding rates of the spike proteins of both viruses to ACE2.
The most precise measures available in the literature are kSARS−2 = (2.3±1.4)105nM−1s−1
and kSARS = (1.7±0.7)105nM−1s−1 (table 1 in [66]). Although the error bars are huge, the
greater rate constant of SARS-CoV-2 agrees with the more precisely determined binding
affinity from the same table (KSARS−2 = (1.2±0.1)nM and KSARS = (5.0±0.1)nM), and
from Ref. [65] that indicates that the spike protein of SARS-CoV-2 has greater affinity
for ACE than the one of SARS-CoV. In that paper only one experiment was performed
instead of five in Ref. [66] and the binding rate constant was greater for SARS-CoV, which
is consistent with the large statistical errors measured in Ref. [66]. Thus, although the
available data is quite noisy, the best available evidence suggests that the binding rate
of SARS-CoV-2 spike protein is on the average faster than for SARS and the binding is
more stable, which may also contribute to faster absorption giving the virus more time
to perform membrane fusion.
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For predicting the CFR of the 2003 SARS outbreak, I used the parameters of SARS-
CoV-2 and rescaled them with the ratio between the kinetic binding constant kon of the
two spike proteins: aSARS = aSARS−2/1.35 and bSARS = bSARS−2/
√
1.35. I obtained the
lethality profile as exp(−aSARSA + bSARS
√
A), where A is the ACE2 level of each gender
and age class, and multiplied it times a constant factor that accounts for the different
fraction of undetected cases, which was the only free parameter determined through a fit.
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Fita v(A)b Accr. P (ti)
d − ln(Pd)e Errorf ag bh ci Dataj
0.03 5.2± 0.1 1.1± 0.1 ES
exp aA+ b 0.09 6.4± 0.3 0.5± 0.2 IT
0.11 6.3± 0.4 1.6± 0.2 DE
0.37 0.5± 0.2 5.5± 0.4 ES
1E Const > 0 E − a
A
+ b 0.41 0.6± 0.3 6.0± 0.6 IT
0.48 0.5± 0.3 6.6± 0.7 DE
0.19 5.7± 0.4 0.1± 0.3 ES
2E Decr > 0 E − a
A
+ b 0.30 5.4± 0.4 0.5± 0.1 IT
0.23 6.7± 0.4 0.4± 0.3 DE
0.07 6.8± 0.5 0.6± 0.3 ES
3E Decr 0 E a
√
A + b 0.21 6.4± 0.5 0.2± 0.2 IT
0.17 8.1± 0.4 0.6± 0.1 DE
0.04 0.2± 0.1 2.5± 0.5 8.1± 0.6 ES
1G Const > 0 G a
A2
− b
A
+ c 0.10 0.3± 0.3 3.3± 1.8 9.4± 2 IT
0.14 0.3± 0.4 3.3± 2 10± 2 DE
0.01 6.1± 1 0.7± 1 0.7± 0.4 ES
2G Decr 0 G aA− b
√
A + c 0.04 13± 1.5 8± 2 2.4± 0.9 IT
0.06 16± 1 13± 2 5.2± 0.5 DE
0.01 7.0± 0.1 0.7± 0.1 0.3± 0.1 ES
3G Decr > 0 G aA− b
√
A+ c√
A
0.04 11± 0.8 4.2± 0.9 0.4± 0.2 IT
0.06 12± 0.8 5.2± 1 1.1± 0.1 DE
0.01 6.9± 0.5 1.1± 0.5 0.85 ES
2G2 Decr 0 G aA− b
√
A + c 0.07 7.6± 0.5 1.1± 0.4 0.525 IT
0.09 8.7± 1 2.0± 1 1.425 DE
0.08 5.09 0.97 0.01 SA
2G1 Decr 0 G aA− b
√
A + c 0.13 5.66 0.93 0.10 SA
0.01 6.49 1.74 0.58 SA
Table 1: Fit results. (a) Type of fit. (b) Dependence of viral velocity on receptor level A.
I test only the constant and decreasing regime because the increasing regime contradicts
the data. (c) Critical level of ACE2 below which the patient dies. If Acrit. = 0 death
happens later and the CFR depends less on the initial level of ACE2. (d) Distribution
of the response time of the immune system, either exponential (E) or Gaussian (G). (e)
Functional form of the logarithm of the death probability (estimated as CFR) versus the
initial receptor level A computed with the mathematical model under hypothesis b, c and
d. (f) Relative mean square error 1−r2 of the fit regularized with rescaled ridge regression
(i.e. the error is not the minimal possible), imposing that all fit parameters are positive.
(g-i) Fit parameters and statistical error computed with bootstrapping. (j) Fitted CFR
data. ES=Spain, IT=Italy, DE=Germany, SA=SARS 2003 Hong Kong. In fit 2G2 only
the parameters a and b are fitted while c is set to get a given value of the relative error
of the parameters. In fit 2G1, for the 2003 SARS, only the multiplicative parameter c
is fitted while a and b are predicted based on the corresponding parameters of Spain,
Italy and Germany and the ratio between the kinetic rate constant of the spike proteins
of SARS-Cov and SARS-Cov-2. Note that two-parameter fits from Italy and Germany
coincide within the error except for a multiplicative factor (additive in the logarithm)
despite the fraction of undetected cases of the two countries are very different.
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